If left undiagnosed and untreated for a prolonged period, fatty liver disease can progress to more serious conditions, such as cirrhosis and liver cancer.
All over the United States, countless research projects designed to improve outcomes have lost funding or been shut down. Even screening efforts targeting patients in impoverished communities have been impacted by these policies.
The first 250 patients has been enrolled in the CORCINCH-HF U.S. pivotal trial evaluating the AccuCinch Transcatheter Left Ventricular Restoration System in patients with HFrEF.
Electrophysiology specialist Vivek Reddy, MD, and colleagues reviewed data from more than 17,000 patients, presenting their findings in Nature Medicine.
The grant will fund a team at the UCLA Health Jonsson Comprehensive Cancer Center working to identify genetic biomarkers capable of predicting RT side effects.
A paper in the Journal of Vascular and Interventional Radiology offers new guidance on how ablation volumes affect renal function in solitary kidneys and highlights ranges that pose the least risk to patients.
The more an individual’s score changes, the greater the odds are of them being diagnosed with cancer in the near future, new research presented at SIIM 2024 suggests.
The new data suggest that admitting patients for observation and additional imaging to monitor for delayed intracranial hemorrhage might often be unnecessary.
